Population Pharmacokinetic Modeling of Total and Free Ceftriaxone in Critically Ill Children and Young Adults and Monte Carlo Simulations Support Twice Daily Dosing for Target Attainment

被引:15
|
作者
Girdwood, Sonya Tang [1 ,2 ,3 ]
Dong, Min [2 ,3 ]
Tang, Peter [3 ,4 ]
Stoneman, Erin [5 ]
Jones, Rhonda [5 ]
Yunger, Toni [5 ]
Ostermeier, Austin [1 ,3 ]
Curry, Calise [1 ]
Forton, Melissa [1 ]
Hail, Traci [1 ]
Mullaney, Randi [1 ]
Lahni, Patrick [5 ]
Punt, Nieko [6 ,7 ]
Kaplan, Jennifer [3 ,5 ]
Vinks, Alexander A. [2 ,3 ]
机构
[1] Cincinnati Childrens Hosp Med Ctr, Div Hosp Med, Dept Pediat, Cincinnati, OH 45229 USA
[2] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Clin Pharmacol, Cincinnati, OH 45229 USA
[3] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45267 USA
[4] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Pathol, Cincinnati, OH USA
[5] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Crit Care Med, Cincinnati, OH USA
[6] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
[7] Medimat, Maastricht, Netherlands
基金
美国国家卫生研究院;
关键词
beta-lactams; ceftriaxone; critically ill; pharmacokinetics; pharmacodynamics; PEDIATRIC INDEX; CLEARANCE; PERFORMANCE; MORTALITY; SEPSIS;
D O I
10.1128/AAC.01427-21
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Critical illness, including sepsis, causes significant pathophysiologic changes that alter the pharmacokinetics (PK) of antibiotics. Ceftriaxone is one of the most prescribed antibiotics in patients admitted to the pediatric intensive care unit (PICU). We sought to develop population PK models of both total ceftriaxone and free ceftriaxone in children admitted to a single-center PICU using a scavenged opportunistic sampling approach. We tested if the presence of sepsis and phase of illness (before or after 48 h of antibiotic treatment) altered ceftriaxone PK parameters. We performed Monte Carlo simulations to evaluate whether dosing regimens commonly used in PICUs in the United States (50 mg/kg of body weight every 12 h versus 24 h) resulted in adequate antimicrobial coverage. We found that a two-compartment model best described both total and free ceftriaxone concentrations. For free concentrations, the population clearance value is 6.54 L/h/70 kg, central volume is 25.4 L/70 kg, and peripheral volume is 19.6 L/70 kg. For both models, we found that allometric weight scaling, postmenstrual age, creatinine clearance, and daily highest temperature had significant effects on clearance. The presence of sepsis or phase of illness did not have a significant effect on clearance or volume of distribution. Monte Carlo simulations demonstrated that to achieve free concentrations above 1 mu g/ml for 100% of the dosing intervals, a dosing regimen of 50 mg/kg every 12 h is recommended for most patients. A continuous infusion could be considered if the target is to maintain free concentrations four times above the MICs (4 mu g/ml).
引用
收藏
页数:17
相关论文
共 3 条
  • [1] Pharmacokinetic parameters over time during sepsis and the association of target attainment and outcomes in critically ill children and young adults receiving ceftriaxone
    Girdwood, Sonya Tang
    Tang, Peter
    Fenchel, Matthew
    Dong, Min
    Stoneman, Erin
    Jones, Rhonda
    Ostermeier, Austin
    Curry, Calise
    Forton, Melissa
    Hail, Traci
    Mullaney, Randi
    Diseroad, Emily
    Punt, Nieko
    Kaplan, Jennifer
    Vinks, Alexander A.
    PHARMACOTHERAPY, 2023, 43 (07): : 609 - 621
  • [2] Population pharmacokinetic/pharmacodynamic target attainment of ceftriaxone 2 g once daily in non-critically ill hospitalized adult patients during the acute phase of infection
    van den Broek, Annemieke K.
    van Schip, Anne
    Visser, Caroline E.
    Bos, Jeannet C.
    Prins, Jan M.
    van Hest, Reinier M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (11) : 3262 - 3272
  • [3] NONMEM population pharmacokinetics and Monte Carlo dosing simulations of imipenem in critically ill patients with life-threatening severe infections during support with or without extracorporeal membrane oxygenation in an intensive care unit
    Jaruratanasirikul, Sutep
    Boonpeng, Apinya
    Nawakitrangsan, Monchana
    Samaeng, Maseetoh
    PHARMACOTHERAPY, 2021, 41 (07): : 572 - 597